FDA Cites Generics Maker Heritage Over Postmarket Reporting Woes

Generic Line
A A
Generic manufacturer Heritage Pharmaceuticals has been hit with a warning letter for what the FDA calls “serious violations” of postmarket reporting requirements.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00